1 Title: Patients with sickle cell disease presented dysregulated plasma Rb/K ratio and Gamma-

- 2 glutamyl cycle in red blood cells
- 3

Author (s): Shruti Bhatt¹, Amit Kumar Mohapatra², Apratim Sai Rajesh^{3,#}, Satyabrata Meher⁴,
Pradip Kumar Panda⁵, Ranjan Kumar Nanda^{2*} and Suman Kundu^{1,6*}

- 6
- 7 ¹Department of Biochemistry, University of Delhi South Campus, New Delhi 110021, India
- ²Translational Health Group, International Centre for Genetic Engineering and Biotechnology, New
 Delhi 110067, India
- ³Department of Biosciences and Biotechnology, Fakir Mohan University, Balasore 756019, India
- ⁴Multi-disciplinary Research Unit, Veer Surendra Sai Institute of Medical Science and Research, Burla,
 Sambalpur, Odisha, 768017, India
- 13 ⁵Sri Sri College of Ayurvedic Science and Research, Sri Sri University, Cuttack, Odisha 753015, India
- 14 ⁶Department of Biological Sciences, Birla Institute of Technology and Science Pilani, K.K.Birla Goa
- 15 Campus, Goa 403726, India
- 16

17 *Correspondence:

- 18 Suman Kundu, BITS Pilani, K.K.Birla Goa Campus, Goa 403726 and University of Delhi South
- 19 Campus, New Delhi 110021, India;
- 20 Telephone No: +91-832-2580101
- 21 Email address: swundu@goa.bits-pilani.ac.in; skundu@goa.bits-pilani.ac.in; skundu@goa.bits-pilani.ac.in; skundu@goa.bits-pilani.ac.in; skundu@goa.bits-pilani.ac.in; skundu@south.du.ac.in; skundu@south.du.ac.in; skundu@south.du.ac.in; skundu@south.du.ac.in; skundu@south.du; skundu@sout
- 22 Ranjan Kumar Nanda, Translational Health Group, International Centre for Genetic Engineering and
- 23 Biotechnology, New Delhi 110067, India
- 24 Email address: ranjan@icgeb.res.in
- 25
- ²⁶ [#]Present affiliation: COVID-19 laboratory, Department of Microbiology, Veer Surendra Sai Institute of
- 27 Medical Science and Research, Burla, Sambalpur, Odisha, 768017, India
- 28 29
- 30 **Running title:** RBC metabolome in sickle cell disease
- 31
- 32
- 33
- 34
- 35
- 36
- 37

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

39 Abstract

Patients suffering from sickle cell disease (SCD) present with multifactorial pathology, and a detailed understanding of it may help to develop novel therapeutics. In this study, the plasma elemental (²⁴Mg, ⁴⁴Ca, ⁵⁷Fe, ⁶³Cu, ⁶⁶Zn, ⁷⁷Se, ⁸⁵Rb, ²⁰⁸Pb, and ³⁹K) levels of SCD patients (n=10, male: 50%) and control groups (trait and healthy; n=10 each; male: 50%) were profiled using inductively coupled plasma mass spectrometry (ICP-MS). Additionally, comparative global erythrocyte metabolomics of SCD (n=5, male:100%) and healthy controls (n=5, male:100%) were carried out using liquid chromatography-mass spectrometry (LC-MS). SCD patients had higher plasma ²⁴Mg, ⁴⁴Ca, ⁶⁶Zn, ²⁰⁸Pb, and ³⁹K levels and lower levels of ⁵⁷Fe, ⁷⁷Se, and ⁸⁵Rb compared to controls. These changes in elemental levels, with a decreased Rb/K ratio in the SCD group, may explain the observed frequent hemolysis and severe dehydration with oxidative stress in patients. Mass spectrometry analysis of red blood cells (RBCs of SCD (n=5) and healthy controls (n=5) identified 442 unique metabolic features which separately clustered both the study groups in principal component analysis (PCA). A set of 136 features showed differential (p<0.05; log₂fold change>±1) regulation and was involved in Dglutamine/D-glutamate, sphingolipid, arginine biosynthesis, glutathione and glycine, serine and threonine metabolism. Interestingly, higher pyroglutamic acid levels were observed in the sickle shaped-RBCs indicating a perturbed gamma-glutamyl pathway in SCD patients. Supplementation of the depleted trace metals and targeting the perturbed metabolic pathways in the RBCs of SCD patients may provide avenues for the development of alternate therapeutics.

62 Key words: sickle cell disease; metabolomics; ionomics; red cells; oxidative stress; mass spectrometry.

91 Graphical abstract



114 **1. Introduction**

115

116 WHO has recognized sickle cell disease (SCD), the first known human molecular disorder, as 117 a global health pandemic. SCD cases are predicted to increase from 300,000 to 400,000 by 118 2050 and the majority (2/3) of it was recorded in Africa and India [1-5]. SCD is caused by a 119 genetic mutation that translates into the substitution of valine by glutamic acid, at the 6th 120 position in the β chain of the hemoglobin molecule leading to a structural variant known as 121 Hemoglobin S (HbS) [6-8]. HbS has a reduced oxygen affinity, and deoxygenation near tissues 122 leads to exposure of hydrophobic sites on individual T-state HbS molecules [9].

Exposed hydrophobic sites act as a nucleus on the HbS molecule, aggregating and forming a 14 nm fiber leading to the sickle shaped RBCs (SS-RBCs). SS-RBCs block the blood vessels leading to an impaired blood supply to organs causing recurrent episodes of acute pain (vaso-occlusive crisis: VOC) and chronic damage leading to poor survival [10-14]. Understanding the detailed pathophysiology of SCD at the molecular and elemental level will be useful to identify targets for better clinical management [15].

Multi-omics studies using liquid chromatography and inductively coupled plasma mass 129 spectrometry (LC-MS/ICP-MS) are useful to capture the metabolites and elemental details to 130 better understand the disease pathophysiology. Several metabolomic studies have advanced 131 our understanding of various disease pathobiology and have become backbone for the 132 development of alternative therapeutics [16]. Metabolite profiling deciphered that enhanced 133 ADORA2B signaling led to increased plasma adenosine levels, contributing to multiple SCD-134 related complications [17]. It also captured an enhanced level of circulating sphingosine-1-135 phosphate (S1P), a bioactive lipid, in both SCD mice and humans [18]. The Sphk1-led S1P 136 137 increase reprogrammes the metabolic balance via the release of glycolytic enzymes in the cytosol [19], towards the Embden Meyerhoff pathway (EMP) rather than the Hexose 138 monophosphate pathway (HMP) [20]. The metabolic switching induces sickling via elevated 139 140 production of 2,3-BPG (2, 3 bisphosphoglycerate) [21], signals inflammation and tissue 141 damage via the S1PR1 (S1P receptor 1) receptor on immune cells (myeloid lineage) [22]. A dysregulated Land's cycle, evident from increased lysophosphatidylcholine and arachidonic 142 143 acid levels in SS-RBC, was reported using comparative blood metabolomic profiling of Sickle-Tg mice [23]. Interestingly, these few unbiased metabolic analyses have delivered a massive 144 thrust to in-vitro, pharmacological, preclinical and human studies targeting the ADORA2B and 145 SphK1-S1P-S1PR1-IL-6 signaling cascades to decipher alternative therapeutic strategies 146 [24]. For example, PEG-ADA(adenosine deaminase deficiency), a clinically relevant drug used 147 to treat ADA-deficient patients, reduced elevated adenosine levels, sickling, splenomegaly, 148 multiple tissue damage, and pain [17]. Alternatively, a decrease in adenosine production can 149 be achieved via CD73 inhibitor [e.g., adenosine 5'- $(\alpha,\beta$ -methylene) diphosphate], reduced 150 sickling and multiple organ damage [25]. 151

Similarly, a molecular antagonism of ADORA2B and SphK1 by PSB1115 and PF543, 152 respectively, potently decreases sickling, inflammation and pain [26, 27]. However, only a 153 fraction of these limited studies explored the metabolic profile of SS-RBCs derived from SCD 154 patients [28-30]. Most have been performed on erythrocytes derived from cultured human 155 RBCs and SCD-transgenic mice. Additionally, the previous studies fall short of capturing 156 comprehensive pathological effects of sickle cell haplotypes including Senegal (SEN), Benin 157 (BEN), Bantu or Central African Republic (CAR), Cameroon (CAM) and Arab-Indian 158 159 (ARAB/AI) that represent the ethnic group or geographical region from which patients 160 originated. To the best of our knowledge, no such investigation has been reported for Indian SCD diaspora. Thus, it would be interesting to investigate metabolic fingerprint of SS-RBCs 161 (primarily Arab-Indian haplotype). 162

Furthermore, it has been repeatedly pressed that multi-omics can supplement and 163 support pathophysiological understanding of various physiological stress [31]. Morphological, 164 biochemical and metabolic changes/alterations induced by multiple pathological conditions 165 can be correlated to the alterations in the concentration of elements in biofluids. The most 166 notable example links RBC clearance with intracellular calcium levels [32, 33]. However, few 167 studies establish the impact of stressors on the homeostatic loss of ions associated with SCD 168 [34-36]. Inductively-coupled plasma mass spectrometry (ICP-MS) is a recent evolution of a 169 decades-old analytical technique to measure elements at trace levels in biological fluids [37]. 170

Thus, sparse and restricted reports on the perturbed metabolic pathways in RBCs and 171 plasma elemental levels in SCD patients forged an exciting research avenue to be explored [29, 172 38-40]. In this study, a comparative plasma elemental composition was monitored between 173 SCD and control (traits and healthy) groups and global RBC metabolome profiling between 174 175 SCD and healthy controls was performed. This study provides an unique opportunity to 176 integrate metabolomic and ionomic fingerprints to undertstand dysregulated metabolic pathways and identify markers associated with SCD. The lack of validated biomarkers for SCA 177 severity represents a void in the state of knowledge of SCD that creates a critical roadblock in 178 179 the design of clinical trials, the development of novel therapies and the emergence of precision medicine for SCD patients. 180

181

182 **2. Materials and Methods**

183 **2.1 Ethics statement**

All participants provided informed consent before participating in the study. This study was approved by the Institutional Ethics Committee of Sri Sri University, Cuttack, Odisha (SSCASRH/IEC/006/21) and University of Delhi South Campus, Delhi, India (UDSC/IEC/2021/Project/5.10.2021/4). The human studies reported in this study abide by the Declaration of Helsinki principles.

189 2.2 Study participants

For this study, blood samples were collected from a cohort of ten adult SCD patients with hemoglobin SS (HbSS, n=10, male 50%) disease (Supplementary Table S1), sickle cell trait individuals (hemoglobin AS: HbAS, n=10, male 50%) and ten healthy adults (controls, HC, n=10, male 50%). Written informed consent was obtained from all patients and controls. All protocols and procedures were approved by institutional ethics committees of the collaborating institutes handling patient samples.

196 **2.3 Sample collection and processing**

For this study, blood samples were collected from SCD patients in EDTA with hemoglobin SS 197 198 disease and healthy adults (controls). Complete blood count (CBC) determined the clinical profile of participants; cellulose electrophoresis, PCR, and HPLC are presented in 199 200 Supplementary Tables 1 and 2. The participants were enrolled according to the approved 201 inclusion and exclusion criteria with consent (S.1.2). The inclusion criteria were a confirmed diagnosis of sickle cell disease by HPLC. Individuals who had received a transfusion were 202 excluded from the study. All patients were receiving analgesic treatments. Blood samples, 203 taken from patients with SCD, were characterized by their sickling properties [41]. Blood tubes 204 were then centrifuged at 2000 ×g for 10 min to separate the RBCs and plasma and were 205 aliquoted into equal volumes (0.5 ml). Plasma samples were stored in a -80 °C freezer until 206 207 analysis. Samples were processed according to a biphasic liquid-liquid extraction (LLE) protocol. Briefly, RBC metabolism was quenched by extracting metabolites into 208 methanol/water/chloroform solvents. 209

210 2.3.1 Untargeted metabolite profiling of sickle RBCs

- The 0.5 ml aliquots of human donor erythrocytes (Sri Sri University) that had been pre-treated
- with heparin anti-coagulant were placed in 2.0 ml microcentrifuge tubes (MCT). After adding

internal standards, they were centrifuged at $1000 \times g$ and $4 \circ C$ for 2 min and then placed on ice while the supernatant was aspirated. The RBCs were washed twice with their resuspension in 1x phosphate-buffered saline (PBS) through centrifugation, and finally the supernatant was aspirated to leave an RBC pellet. These wash cycles remove non-erythrocytic metabolites and other compounds that may still be present outside the cells; however, it also delays quenching,

and might leave residual traces of phosphate salts.

219 2.3.2 Metabolite extraction

To the RBC pellet of each tube, 0.15 mL of ice-cold, ultrapure water (Milli-Q Millipore, 220 Mississauga, Canada) was added to resuspend the erythrocytes. The tubes were first plunged 221 into the dry ice for 30 seconds followed by 20 seconds of incubation in the water bath at 37 °C 222 to quench metabolism and lyse the cells. After quenching with dry ice, 0.6 ml of methanol at 223 20 °C temperature was added, and the tubes were then vortexed to ensure complete mixing. 224 225 The tubes were then plunged again into dry ice where 0.45 ml of chloroform was added to each tube. These tubes were vortexed briefly every 5 min for 30 min, and between each brief 226 vortexing interval, they were placed in a cold bath. After 6 brief vortexes, the tubes were 227 transferred to room temperature and 0.15 ml of ice-cold, ultrapure water (Milli-Q Millipore, 228 229 Mississauga, Canada) was added to drive the phase separation between methanol and chloroform. The tubes were centrifuged at 1,000 ×g for 2 min at 4 °C so that a clear separation 230 of the two phases could be observed above and below the compact disk of erythrocytes. After 231 centrifugation, the tubes were transferred to a -20 °C freezer for an overnight incubation to 232 allow residual chloroform to precipitate out of the aqueous methanol phase. The two liquid 233 234 phases in each tube were transferred to separate 1.5 mL microcentrifuge tubes without 235 disturbing the compact disk of erythrocytes or transferring any erythrocytes to the new tubes. The final volumes translated to a methanol/water/chloroform ratio of 4:2:3 for extraction and 236 phase separation. The samples were then dried with speed-vac and resuspended in 0.2 mL LC 237 mobile phase (97.9% ultra-pure water / 2% acetonitrile / 0.1% formic acid) [42]. 238

239 2.3.3 UPLC-Q-Exactive Plus Orbitrap MS/MS analysis

All the samples were analyzed using an UHPLC system (UHPLC Dionex UltiMate[®] 3000, 240 Dionex, Thermo Fisher Scientific, United States) that was controlled with Thermo Xcalibur 241 software (Thermo Fisher Scientific, United States). The samples were separated using a 242 Kinetex UPLC C18 column (100 × 2.1 mm, 1.9 µm; Phenomenex, Torrance, CA, United 243 States). The mobile phase consisted of solvent A (0.1% formic acid) and solvent B (acetonitrile 244 with 0.1% formic acid). Gradient elution was applied using the following optimized gradient 245 program: A 35-min gradient at a flow rate of 0.3 ml/min with the following conditions was 246 used for separation: 0-5 min, 1% B; 5-10 min, linear gradient from 1-3% B; 10-18 min, linear 247 248 gradient from 3-40% B; 18-22 min, linear gradient from 40-80% B; 22-27 min, column cleaning at 95% B; and 27–35 min, re-equilibration at 1% B. 249

- 250 Mass spectrometry was performed on a Q-Exactive PlusTM Quadrupole-Orbitrap mass
- 251 spectrometer (Thermo Fisher Scientific, United States) in positive ion mode. Data-dependent 252 acquisition method was used for MS/MS of small molecules in the extractions. The complete

acquisition method was used for MS/MS of small molecules in the extractions. The complete MS settings were 70,000 resolution, $1e^{6}$ AGC (Automatic Gain Control), 100 ms max inject

- time, and 100–1500 m/z. The MS/MS settings were 35,000 resolution, 1e5 AGC, 100 ms max
- inject time, 1.0 m/z isolation window, and 30 dynamic exclusions. Three technical replicates
- were run for each extraction, and each technical replicate used a different HCD collision energy
- 257 (25, 30, and 35, respectively).
- 258 Compound DiscovererTM 3.0 (Thermo Fisher Scientific, United States) software was used to 259 analyze the LC-MS/MS data for each extraction in positive ion mode.
- 260 Data normalization and analysis were carried out using MetaboAnalyst 5.0 261 (www.metaboanalyst.ca) [43]. Data exclusion was performed for metabolites with constant 262 values across metabolites and interquartile filtering. Missing values were mean imputed, and

normalization was performed. For univariate analysis, fold change and T-test values were 263 calculated, followed by multiple testing correction based on false discovery rate (FDR). ROC-264 curve (receiver operating characteristic) analysis was also carried out for each metabolic 265 feature, and 95% confidence intervals were calculated using bootstrapping with 1000 266 permutations. Multivariate exploratory analysis was performed using principal component 267 analysis (PCA) and orthogonal projections to latent structures discriminant analysis (OPLS-268 DA). Permutation testing for OPLS-DA was applied to evaluate model stability to parameter 269 addition. Linear support vector machine (SVM) classifiers were built to predict group class 270 using Monte-Carlo cross-validation (MCCV) and balanced subsampling. A total of six SVMs 271 with an increasing number of metabolites (maximum 100) were compared. Model evaluation 272 was performed using ROC curves, and biomarker identification was achieved using the feature 273 ranking method implemented in SVM (S.2.2, Fig. S3a, b, c). 274

275 2.4 Trace metal quantification using inductively coupled plasma mass spectrometry (ICP 276 MS)

Plasma samples of study groups were processed and subjected to ICP-MS to quantify ²⁴Mg, 277 ⁴⁴Ca, ⁵⁷Fe, ⁶³Cu, ⁶⁶Zn, ⁷⁷Se, ⁸⁵Rb, ²⁰⁸Pb, and ³⁹K. Plasma samples (100 μl) were transferred to 278 MG5 vials (Anton Paar, Graz, Austria), and HNO3 (250µl, 70%, #225711 Sigma Aldrich, St. 279 Louis, Missouri, United States, with \geq 99.999% trace metal basis) and H₂O₂ (50µl, 30%, 231 280 #1.07298.1000, Supelco, Inc. Bellefonte, Pennsylvania, USA) were added. Vials were sealed 281 282 using sealers (#411860, Anton Paar). The vials containing the reaction mixtures were digested using a microwave digestion system (Anton Paar, Graz, Austria) ramped up to 300 W in 15 283 min, where it was held for 10 min. The digested samples diluted using trace metal-free water 284 spectrometry (ICP-MS) (18.2) $M\Omega \times cm$) for inductively coupled plasma mass 285 analysis. Digested samples were analyzed using ICP-MS (iCAPTM TQ ICP-MS, Thermo 286 Scientific, USA). Thermo Scientific Qtegra Intelligent Scientific Data Solution (ISDS) 287 software was used for operating and controlling the instrument. The ICP-MS was calibrated 288 using a multi-element standard mix (#92091, Sigma Aldrich, St. Louis, Missouri, United 289 States) prepared in 1% HNO₃ per the manufacturer's instruction. Calibration plots were 290 prepared at 1 ppb to 5 ppm concentrations and showed $R^2 = 0.99$. Digested samples were 291 aspirated using a V-grooved MicroMist DC nebulizer and spray chamber of ICP-MS using a 292 sample capillary (0.55 mm). Samples were then passed through a quartz torch with an injector 293 having a diameter of 2 mm. Here, plasma ionized samples passes through sample cones, 294 followed by a skimmer cone. The experiments were conducted in KED (Kinetic energy 295 dissociation) mode to avoid any polyatomic ion interference. During the run, the nebulizer flow 296 was set at 1.04 l/min with a pressure of 3.20 bar. The peristaltic pump revolved clockwise at 297 298 40 rpm. The quartz torch produced plasma and the exhaust was maintained at 0.49 mbar. 299 Interface temperature was maintained at 29.98°C with a N₂ flow of 14 l/min. The system's sample and skimmer cones were made of nickel with orifices of 1 mm and 0.5 mm, 300 301 respectively. Between sample runs, HNO_3 (1%) was pumped through the nebulizer with a wash-out time of 30 sec to remove any carryover. The complete experiment was carried out 302 with a dwell time of 0.1s. The average of three runs for each element concentration was 303 calculated and exported for further statistical analysis. Comparative trace element levels 304 between study groups (HbSS, HbAS and HbAA) were calculated considering the limit of 305 detection and dilution factors. 306

307 2.4.1 Statistical analysis

An unpaired t-test was performed using Graphpad prism 8 to identify group-specific variations and a p<0.05 was selected as significant.

- 310
- 311
- 312

313 **3. Results**

314

315 **3.1 Clinical characteristics of the study participants**

In this case and control study, a total of 30 study participants belonging to SCD as case and control (sickle cell trait and healthy controls) were used for plasma ionomic and RBC metabolomic profiling. The demographic and clinical characteristics of study participants are presented in Supplementary Tables S1 and S2.

320

321 **3.2** Sickle cell anemia is associated with an altered ionomic profile

From the comparative plasma trace element analysis, significantly higher plasma levels of Mg 322 (p<0.0001), Zn (p<0.0001), Ca (p<0.01), Pb (p<0.01), and K (p<0.01) were observed in SCD 323 patients compared to healthy controls (Fig. 1a, c, d, e, h). Significantly lower plasma levels of 324 325 Fe, Se (p<0.05), and Rb (p<0.01) were observed, indicating higher oxidative stress in SCD 326 patients (Fig. 1b, g and i). However, Cu levels were similar between study groups (Fig. 1f). Overall, the subjects with sickle cell trait had comparable trace metal levels to the healthy 327 controls except for Rb whose levels hovered in between the levels observed in SCD and healthy 328 329 control (Fig. 1i). We found that there was a steady decrease in Rb/K levels in the SCD group compared to the healthy controls (Fig. 1j) 330

331

332 3.3 Metabolomics profiling of RBCs of patients with SCD demonstrated significant 333 deregulation of specific metabolites compared to the healthy controls.

Global metabolomic profiling of RBCs from SCD patients and healthy donors yielded 442 334 335 metabolite features. Principal Components Analysis (PCA) analysis of these analytes showed separate non-overlapping clusters of SCD and healthy groups. The principal components 1 and 336 2 explained 44.2% of the total variance (Fig. 2a). A supervised OPLS-DA model was evaluated 337 to identify significant differentially abundant metabolites between groups and validated using 338 permutation tests (Fig. S2a). A random permutation test (n = 2000) resulted in an interpretation 339 rate (R₂) and prediction ability (Q₂) of 0.999 and 0.891, respectively (Fig. S2b). A set of 10 340 analytes (S.2.2, Fig. S2c) qualified the variable importance in projection (VIP) scores >1.0 and 341 were identified as important metabolites. These metabolites displayed significantly different 342 concentrations between groups, with fold changes >1.0 or <0.5. In the univariate analysis, 136 343 showed differential expression (62/56; up-/down-regulated; FC>; p<0.005) in SCD (Fig. 2b, 344 Table S3 and Table S4). After false discovery rate adjustment, 18 analytes (7/10; up/down 345 regulated) showed significant deregulation. In the RBC of SCD patients, glutathione, 346 aminolevulinic acid, DL-2-aminooctanoic acid, D-glutamine, and aminoadipic acid (Table S3) 347 348 levels were significantly high. Significantly lower levels of N6,N6,N6-trimethyl-L-lysine, dihydrothymine, pyroglutamic acid, 2'-alpha-mannosyl-L-tryptophan and 2-aminoisobutyric 349 acid were observed in the RBC of the SCD patients compared to healthy controls (Fig. 2b, 2c). 350 Hierarchical clustering analysis was performed to identify top 25 significantly dysregulated 351 metabolic features in SCD and healthy control (Fig. 2c). The SVM model evaluation 352 highlighted the common metabolic features (Fig. S3c) with the OPLS-DA (Fig. S2c) and 353 hierarchical clustering analysis (Fig. 2c), i.e., thiazolidine-4-carboxylic acid, N-[(3-exo)-8-354 Benzyl-8-azabicyclo[3.2.1]oct-3-yl]-2-methylpropanamide, ethyl-3-phenylpropionate, 355 meprobamate, N-BOC hydroxylamine. Interestingly, amongst the common metabolic features, 356 357 thiazolidine-4-carboxylic acid and its derivatives have been reported reduce oxidative stress induced cell death [44]. 358

359

360 3.4 Functional pathway analysis

The significantly dysregulated metabolites in SCD group were selected for the KEGG pathway
 analysis using MetaboAnalayst (<u>https://www.metaboanalyst.ca</u>). D-glutamine and D-

363 glutamate metabolism (p-value = 0.0006, Fig. S6a), aminoacyl-tRNA biosynthesis metabolism 364 (p-value = 0.0009), sphingolipid metabolism (p-value = 0.0009), arginine biosynthesis (p-value 365 = 0.00099), glycine, serine and threonine metabolism (p-value = 0.004, Fig. S6b), beta-alanine 366 metabolism (p<0.005), arginine and proline metabolism (p<0.007), glutathione metabolism 367 (p<0.009, Fig. S6c), glutathione metabolism (p<0.01), and ether lipid metabolism (p<0.012) 368 were significantly altered in the RBC of SCD patients compared to the control group (Fig. 2d).

369

4. Discussion

The overwhelming significance of RBCs stems from the enormous abundance of hemoglobin.
Any alteration in structural and functional attributes of hemoglobin can translate into
irregularities in RBC functions. These irregularities can have different clinical complications
a b c d



Figure 1. Plasma trace element levels of sickle cell patient (HbSS), sickle cell trait (HbAS) and healthy control (HC) and their ratio showed significant differences. a) Mg, b) Fe, c)

383 Ca, d) Zn, e) Pb, f) Cu, g) Rb, h) K, i) Se, j) Rb:K. *p < 0.05, **p < 0.01, ***p < 0.001 **** p

384 <0.0001; HbSS: Sickle cell disease; HbAS: Sickle cell trait; HC: Healthy control.

385

inside the human body [45-47]. The RBCs are designated as a simple model to study cellular mechanisms due to less epigenetic, transcriptional and translational complications to regulate the cross-talk amongst various pathways [48-50]. However, recent omics studies highlight the existence of a complex network of cytosolic enzymes which regulate the energetics and functioning of RBCs [51, 52]. Physical and pathological stresses can alter the metabolic equilibrium and accelerate disease progression. Thus, an in-depth understanding is required to deconstruct the highly interlinked stressed RBC pathophysiology [53].

Enhanced hemolysis observed in SCD patients might be contributing to the observed higher plasma Mg level (p<0.001) [54]. This finding is in agreement with observations by Olukoga, A. O et al. (1990) [55] which establishes a negative correlation between erythrocyte and plasma Mg in the SCD cohort [56]. In contrast, low serum Mg levels have been reported in SCD patients due to Mg homeostasis [57, 58].



Figure 2. Pertubed RBC metabolic fingerprint observed in sickle cell disease patients (HbSS) compared to the healthy control (HC). a) PCA score plot showed RBC metabolites (n=442) of SCD patients cluster away from the healthy controls. b) Volcano plot highlighting the dysregulated erythrocyte metabolites in SCD (HbSS) compared to the healthy control (HC). c) Hierarchical Clustering representing the distribution of 25 important RBC metabolites in SCD patients and healthy

423 controls. Columns correspond to samples, and rows to individual metabolites. The color scale indicates 424 the relative abundance of metabolites: red being the most abundant and blue the less abundant 425 metabolites. d) Metabolic pathways altered in the RBCs of SCD patients compared to healthy controls. 426 The pathway impact values (x-axis) represent the influencing factor of topological analysis, and the – 427 log(p) (y-axis) represents the p-value of the pathway enrichment analysis. The vital metabolic pathways 428 were defined as having -log(p) > 2 and pathway impact factor > 0.2.

429

430 Similarly, RBCs contain 10-15% of the total cellular pool of calcium. Sickle cells show increased Ca as compared to normal cells in the oxygenated state [59]. Malinovská V et al. 431 (1991) reported that stress conditions increase plasma Ca levels [60]. Higher plasma Ca levels 432 as observed in SCD patients can be attributed to frequent hemolysis due to prolonged stress in 433 SCD patients [61]. However, in SCD an accumulation of intraerythrocytic Ca has been reported 434 due to malfunction of Ca^{2+} transporters [33]. Higher plasma Ca levels as observed in SCD 435 patients can be attributed to frequent hemolysis due to prolonged stress in SCD patients [62]. 436 An increased intracellular Ca concentration induces alteration to calcium-sensitive potassium 437 (K⁺) channel protein 4 (also known as the putative Gardos channel and K–Cl cotransporter 1 438 439 (KCC1), KCC3 and/or KCC4 [63], resulting in potassium-efflux and decreased cell volume [64-66], which in turn increases the stiffness of RBC. Similarly, we also observed higher 440 plasma K levels corroborating earlier reports [67-71]. Thus, K⁺ is an important indicator of 441 SCD, however, its measurement to assess the severity in many pathophysiological conditions 442 can be erroneous due to factors like pseudohyperkalemia and poses a challenge [72]. 443

Another similar group I alkali metal, rubidium (Rb^+) was significantly lower (p<0.01) 444 in SCD patients compared to the trait and control group. It shares similar biochemical 445 properties and readily exchanges with K⁺ and thus, can be a useful proxy for K⁺. Although its 446 biological function still needs further understanding, ⁸⁶Rb's prominent presence was utilised to 447 measure basal metabolic rate, establishing a correlation between its radioactive turnover and 448 449 K^+ concentration[73]. We are the first to report a correlation between plasma Rb and K^+ 450 concentration, which significantly decreased from healthy to trait and even decreased further in the SCD group. Rb may have the potential to be used as a marker to assess the severity 451 452 associated with sickling. Rb has unique neurophysiological and neuroprotective properties [74-76]. Kordjazy et al. (2015) found that mice administered with Rb showed less depression-like 453 behaviour through changes in the hippocampus [77]. Recent clinical trials and studies have 454 widely reported that SCD patients suffer from neuro-cognitive complications [78-80]. 455 Neurocognitive impairment have been reported in children with SCD, which affects their 456 visuo-spatial memory(14.8%), IQ (85.4%) and copying (68.2%) [79, 81, 82]. These studies 457 indicate that SCD can lead to the development of neuro-complications. Thus, Rb's beneficial 458 role in improving SCD patients' neurocognitive complications can be further explored. 459

We observed significantly higher plasma lead levels in SCD compared to the trait and 460 healthy cohort. These findings align with previous studies that have correlated BLL (Blood 461 lead level) levels with moderate and severe anemia [83]. In addition to neurological toxicity, 462 Pb can worsen sickle cell anemia by impairing heme synthesis and increasing the rate of red 463 blood cell destruction [84]. Schwartz et al (1982) showed a dose-dependent increase in anemia 464 in children with blood lead levels near 25 µg/dl [83, 85]. A linear decrease in hemoglobin was 465 reported in children with increased BLL (BLL >30 μ g/dl) by Drossos et al (1985) [86]. 466 Although these findings indicate a relationship between Pb levels and SCD, a more detailed 467 468 analysis is required to solidify these claims.

High plasma Zn levels of the SCD group was observed compared to trait and control
group that does not corroborate with earlier reports [34, 87]. An increased iron (Fe)
concentration in the intestinal lumen may antagonize the uptake of Zn [88]. Zn concentrations
have been inversely correlated to Copper (Cu) levels [87, 89]. This depletion of Cu could
impair iron absorption [90]. However, no such relationship was observed in our present study

and no significant change in Cu levels was observed across the group. On the contrary, a steady

Fe increase was observed in trait and healthy group (p<0.05), which indicates disrupted Fe homeostasis and most often caused by excessive urinary loss of iron as reported by some studies [91, 92].

Selenium (Se) is an essential component of mammalian enzymes like glutathione 478 peroxidases (GPx) [93, 94], providing antioxidant defence against ROS. Erythrocytes of Se-479 deficient rats failed to protect hemoglobin from oxidative damage in the presence of ascorbate 480 or H₂O₂ or glutathione [94]. Se deficiency is known to alter erythroid parameters like RBC, 481 HCT, HGB, and MCHC (P < 0.05) and makes erythrocytes osmotically fragile [95]. The family 482 is involved in oxido-reduction reactions and these reactions occur in diverse tissues and 483 physiological pathways. Se supplementation has preventive and therapeutic role in diverse 484 disease conditions [96-100]. Plasma Se levels were highest in the healthy and lowest in the 485 486 SCD group (p < 0.05); so Se supplementation may be beneficial to SCD patients.

487

488 4.1 Metabolic insights in sickle RBCs indicate an altered Gamma-Glutamyl cycle which 489 fuels ATP depletion from sickle red blood cells

490 The main oxidative damage control system in RBCs, the glutathione pathway, has been reported to be altered in HbS red blood cells [101]. There is increasing evidence that this 491 alteration leads to oxidative stress with a negative domino effect on the pathophysiology of 492 493 SCD [61]. ROS can be derived non-enzymatically (Fenton chemistry) from denatured sickle hemoglobin (Hb S) moieties and lipid peroxidation or derived enzymatically by the action of 494 495 NADPH oxidase. ROS damage RBC membranes and decrease cell deformability, which 496 contributes to the pathophysiology of SCD [102]. Plasma-free hemoglobin (Hb) and iron chelates are by-products of hemolysis that can also act as oxidants [103]. To counteract ROS, 497 mammalian cells have antioxidant pathways involving reduced glutathione (GSH), NAD(H), 498 499 NADP(H), glutamine and nitric oxide (NO), which are complex and interlinked. Glutathione exists in a reduced (GSH) and oxidized (GSSG) form. The thiol reductant, GSH, scavenges 500 ROS such as hydrogen peroxide and lipid peroxides [103, 104]. GSH can also interact with Hb 501 to form glutathiol-hemoglobin (G-Hb) which reduces the propensity for sickling 502 [105]. Similarly, we observed alterations in glutathione pathway along with disruptions in 503 504 glutamine/glutamate metabolism, which are the main oxidative damages control system in RBCs of HbS cells. 505

Significant disruptions in glycine, serine, and threonine metabolism with lower 5-506 aminolevulinate levels (p-value<0.01), which is a by-product of glycine, indicate lower glycine 507 levels (Fig. 3, Fig. S6c). Chronic oxidative stress leads to increased GSSG efflux that exceeds 508 509 the rate of GSH synthesis [106]. However, rapid efflux of GSSG leads to NADPH depletion, which was observed in our study. Thus, de novo GSH synthesis becomes critical in these 510 oxidative stress conditions and needs glycine, glutamate, and cysteine in an ATP-dependent 511 biosynthesis. Catabolism of GSH via membrane mounted gamma-glutamyl transpeptidase 512 (GGT) followed by removal of gamma-glutamyl moiety from GSH by gamma-glutamyl 513 transpeptidase yields cysteinyl-glycine conjugates (Cys-Gly) and g-glutamyl-amino acid (G-514 Glu) as products. Hydrolysis of these conjugates by ectoprotein dipeptidases (DPT) yields 515 cysteine and glycine. The g-Glu, glycine and cysteine enter the cell through specific 516 transporters. The g-glutamyl with an amino acid derivative enters the cell and gamma-glutamyl 517 cyclotransferase (γ -GCT/GGCT) converts to 5-oxoproline and the corresponding amino acid. 518 5-oxoprolinase (OXP) coverts 5-oxoproline (pyroglutamic acid) to glutamate in a ATP 519 dependent manner. Oxoproline is converted to a dipeptide i.e. g-glutamylcysteine by 520 521 combining glutamate and cysteine by gamma-glutamylcysteine synthetase (y-GCS/G-GCS) in a two-step reaction which utilizes an ATP per catalytic step. This g-glutamyl cysteine can either 522 act as substrate for GGCT to recycle to 5-oxoproline or it can be converted to GSH by the 523

addition of glycine through GSH sythetase (GS) activity with the usage of an ATP molecule[106-108].

ATP production and antioxidant systems within the RBC exploit Hb-based O₂-transport 526 to respond to various physiologic and pathophysiologic stresses. RBCs produce energy through 527 the hexose monophosphate pathway (HMP) and glycolysis, only via the Embden-Meyerhof 528 pathway (EMP), which generates ATP [109]. The HMP route produces NADPH, which powers 529 the thiol-based antioxidant system critical for maintaining homeostasis in the O₂-rich RBC 530 [110]. For example, O₂ offloading promotes glycolysis to generate both 2,3-BPG (a negative 531 allosteric effector of Hb O₂ binding) and ATP. Dynamic regulation of ATP ensures the 532 functional activity of ion pumps, cellular flexibility, drives metabolic reactions and vaso 533 regulation/dilation under hypoxic stress (Fig. 3). A toggle between frequency of EMP and HMP 534 is regulated by the assembly of an EMP protein complex upon the cytoplasmic domain of the 535 536 band 3 membrane protein [cdB3, also known as anion exchanger 1 (AE1)] [111-118]. 537 Metabolite flux through EMP vs. HMP oscillates depending on the Hb conformation (oxygenation state) and cdB3 phosphorylation. RBC deoxygenation promotes the generation 538 of ATP, while full oxygenation of RBCs promotes NADPH generation [109, 119]. Rogers and 539 540 co-workers (2009) showed that RBC antioxidant systems fail when HMP flux is blunted by altered cdB3 protein assembly/phosphorylation caused by aberrant Hbs or hypoxia [109, 120, 541 542 121].

543 SS-RBCs are characterized by elevated indices of oxidative stress and depressed ATP levels[122], as well as elevated 2,3-DPG. Recently published evidence suggests a role for 544 pannexin 1 (Px1) in the release of ATP from RBCs due to Gi protein stimulation in SCD [123, 545 124]. Zhang et al. (2011) showed that an elevated level of plasma adenosine plays a role in the 546 increased concentration of DPG, which contributes to SCD pathophysiology by decreasing 547 O₂ affinity, which in successive turn promotes HbS polymerization, RBC sickling, and 548 549 hemolysis [125]. As a consequence, the hydrolysis of extracellular ATP and accumulation of adenosine are favoured, and signalling via adenosine receptors may promote deoxygenation of 550 sickle Hb and in turn (HbS) polymerization and RBC sickling. 551

The higher levels of pyroglutamic acid or 5-oxoproline in SS-RBCs compared to 552 healthy counterparts can be attributed to an anomaly in salvage pathway of GSH (Fig. S6a, b). 553 5-oxoproline is acted upon by the 5-oxoprolinase enzyme (ATP-requiring enzyme) to yield 554 glutamate [126]. The conversion of glutamate by the action of two consecutive ATP-dependant 555 enzymes yields back GSH (Fig. 3). However, 5-oxoprolinase exhibited slow and inefficient 556 enzyme activity (reaction rate of 0.45 nmol/h), which may explain the increased levels of 5-557 oxoproline in the cells [127]. Also, if γ -GCS fails to find an acceptor cysteine during its 558 559 catalysis, it can autocyclize γ -glutamyl phosphate (intermediate product) to form 5-oxoproline [128]. 560

561 Furthermore, a depleted pool of ATP, cysteine, and glycine due to sickle 562 pathophysiology as discussed above can retard the activity γ -glutamyl cycle enzymes, i.e., 563 OXP, γ -GCS and GS[129]. Bacchawat et al., proposed a similar futile cycle involving ATP-564 dependant γ -glutamyl cycle enzymes like γ -GCS and 5-oxoprolinase, leading to rapid depletion 565 of ATP in cystinosis cells per cycle [130].

Alternatively, we can also hypothesize an abnormal activity of GGCT enzyme that 566 leads to the accumulation of 5-oxoproline by acting on g-glutamyl-AA as a response to a 567 decline in the concentration of cellular GSH under oxidative stress. Previous reports showed 568 that GGCT reduces oxidative and osmotic stress in RBCs which prevents deformability 569 prolonging their life span [131]. In various cancers, higher GGCT expression was observed 570 571 and reported as a therapeutic target [132]. In SS-RBCs, a deregulated GGCT response leads to ATP depletion and also limits the availability of glycine and cysteine, which are GSH 572 precursors [132]. 573

574 **5.** Conclusion

575

In this study, we reported an altered elemental profile of plasma from sickle cell patients and 576 healthy controls. We observed higher levels of Mg, Zn, Ca, K, and Pb in the plasma of SCD 577 compared to the control groups which corroborated with frequent hemolysis, rampant 578 dehydration of SS-RBCs via ion loss through the Gardos channel (due to K⁺ loss), and anemia-579 induced lead accumulation. Additionally, a steady decrease in plasma Rb/K ratio was observed 580 for SCD when compared to trait and healthy control. We found that compromised functioning 581 of y-glutamyl cycle leading to high levels of oxidative stress was associated with SCD. These data 582 could be validated in a larger population while taking other clinical parameters into 583 consideration. This will be useful to gain deeper insight into the biomechanical breakdown of 584 SS-RBCs at the molecular level and critical for identifying novel therapeutic targets for SCD 585 patients. 586

587



588 589

590 Figure 3. Schematics outlining the biomechanical aberration and oxidative stress leading to inoperable y-glutamyl cycle in SS-RBCs. Metabolites in shades of yellow are increased in SS-RBCs 591 592 compared to healthy. Metabolites in shades of blue are decreased in SS-RBCs compared to healthy. 593 Increase in color intensity indicates a higher magnitude. The solid red arrows indicate an altered gamma-594 glutamyl cycle; the yellow arrow depicts altered GSH redox cycle; arrows with dashed outline entails an 595 obstructed metabolic reaction; green arrows/text depicts previously reported pathophysiology of SS-RBCs. GGCT: gamma-glutamyl cyclotransferase; GGT: gamma-glutamyltranspeptidase; γ -GCS: glutamate 596 cysteine ligase; GS: glutathione synthase; OXP: 5-oxoprolinase; γ-Glu-Cys-Gly: glutathione; DP: 597 dipeptidase; HMP: hexose monophosphate pathway; EMP: Embden Meyerhof pathway; ATP: 598 Adenosine triphosphate; ADP: Adenosine diphosphate; AMP: Adenosine monophosphate; Pi: 599 600 phosphate. 601

Funding information

503 SK acknowledges financial support from the University of Delhi (Institution of Eminence grant 504 IOE/FRP/LS/2020/27). SK also acknowledges the financial support from BITS Pilani, K.K. Birla Goa 505 campus (BPGC/RIG/2022-23/09-2022/01; GOA/ACG/2022-2023/Oct/10). RKN acknowledges Core 506 support from the ICGEB New Delhi Component and project support from Department of Biotechnology

- 607 New Delhi. SB acknowledges Department of Biotechnology, Government of India for Research
- 608 Fellowship. ASR is thankful to the Government of Odisha for the Biju Patnaik Research Fellowship.

610 Author contributions

- 611 Shruti Bhatt: Ideated the study, processed samples, designed and performed the ionomic and
- 612 metabolomic experiments, analysed and plotted data, prepared the draft of the manuscript.
- Amit Kumar Mohapatra: Performed ionomic experiments, analysed ionomics data, helped indrafting the manuscript
- 615 Satyabrata Meher, Apratim Sai Rajesh and Pradip Kumar Panda: Recruitment of participants,616 clinical profiling, human sample collection, processing and transport
- 617 Ranjan Kumar Nanda and Suman Kundu: Conceived and supervised the study, analysed data,
- 618 provided tools and reagents, raised funds and drafted and edited the manuscript.

Conflicts of interest

- 621 The authors declare no conflict of interest.

623 Acknowledgement

Prof. Alo Nag, Department of Biochemistry, University of Delhi South Campus, New Delhi, India, is acknowledged for administrative supervision and scientific discussion with SB. Prof. Bishnu Prasad Dash, Adjunct Professor, ICMR-Regional Medical Reasearch Centre, Bhubaneshwar, Odisha, India is acknowledged for scientific discussion with SB and ASR. Ms. Nidhi Mittal is acknowledged for scientific discussions with SB. Central Instrumentation Facility (CIF), University of Delhi South Campus, New Delhi, India, is appreciated for help with metabolomics data collection. Mr Anil Bhansali, Sai Phytoceuticals, New Delhi is appreciated for inspiring the laboratory to investigate sickle cell disease. Dharmender Singh is acknowledged for miscellaneous help to the laboratory.

Figure Legends

Figure 1. Plasma trace element levels of sickle cell patient (HbSS), sickle cell trait (HbAS) and

- healthy control (HC) and their ratio showed significant differences. a) Mg, b) Fe, c) Ca, d) Zn, e) Pb, f) Cu, g) Rb, h) K, i) Se, j) Rb:K. p < 0.05, p < 0.01, p < 0.001, p < 0.001; HbSS:
- Sickle cell disease; HbAS: Sickle cell trait; HC: Healthy control.

Figure 2. Pertubed RBC metabolic fingerprint observed in sickle cell disease patients (HbSS) compared to the healthy control (HC). a) PCA score plot showed RBC metabolites (n=442) of SCD patients cluster away from the healthy controls. b) Volcano plot highlighting the dysregulated erythrocyte metabolites in SCD (HbSS) compared to the healthy control (HC). c) Hierarchical Clustering representing the distribution of 25 important RBC metabolites in SCD patients and healthy controls. Columns correspond to samples, and rows to individual metabolites. The color scale indicates the relative abundance of metabolites: red being the most abundant and blue the less abundant metabolites. d) Metabolic pathways altered in the RBCs of SCD patients compared to healthy controls. The pathway impact values (x-axis) represent the influencing factor of topological analysis, and the -log(p) (y-axis) represents the p-value of the pathway enrichment analysis. The vital metabolic pathways were defined as having $-\log(p) > 2$ and pathway impact factor > 0.2.

Figure 3. Schematics outlining the biomechanical aberration and oxidative stress leading to inoperable γ -glutamyl cycle in SS-RBCs. Metabolites in shades of yellow are increased in SS-RBCs compared to healthy. Metabolites in shades of blue are decreased in SS-RBCs compared to healthy. Increase in color intensity indicates a higher magnitude. The solid red arrows indicate an altered gamma-glutamyl cycle; the yellow arrow depicts altered GSH redox cycle; arrows with dashed outline entails an obstructed metabolic reaction; green arrows/text depicts previously reported pathophysiology of SS-RBCs.

GGCT: gamma-glutamyl cyclotransferase; GGT: gamma-glutamyltranspeptidase; γ-GCS: glutamate cysteine ligase; GS: glutathione synthase; OXP: 5-oxoprolinase; γ -Glu-Cys-Gly: glutathione; DP: dipeptidase; HMP: hexose monophosphate pathway; EMP: Embden Meyerhof pathway; ATP: Adenosine triphosphate; ADP: Adenosine diphosphate; AMP: Adenosine monophosphate; Pi: phosphate.

74.0	
710	References
/11	
/12	[1] L. Pauling, H.A. Itano, et al., Sickle cell anemia a molecular disease, Science 110(2865) (1949) 543-
/13	
714	[2] S.A. Pereira, S. Brener, C.S. Cardoso, A.B. Proietti, Sickle Cell Disease: quality of life in patients with
715	hemoglobin SS and SC disorders, Rev Bras Hematol Hemoter 35(5) (2013) 325-31.
716	[3] F.B. Piel, [Sickle-cell disease: geographical distribution and population estimates], Med Sci (Paris)
/1/	29(11) (2013) 965-7.
718	[4] F.B. Piel, M.H. Steinberg, D.C. Rees, Sickle Cell Disease, N Engl J Med 376(16) (2017) 1561-1573.
/19	[5] F.B. Piel, T.N. Williams, Subphenotypes of sickle cell disease in Africa, Blood 130(20) (2017) 2157-
720	2158. [5] D. C. D. G. T. N. M.(III) and M.T. Chada in Siddle and diverse language 275(07577) (2010) 2010-21
721	[6] D.C. Rees, T.N. Williams, M.T. Gladwin, Sickle-cell disease, Lancet 376(9757) (2010) 2018-31.
722	[7] M.K. Safo, O. Abdulmalik, R. Danso-Danquah, J.C. Burnett, S. Nokuri, G.S. Joshi, F.N. Musayev, T.
723	Asakura, D.J. Abraham, Structural basis for the potent antisickling effect of a novel class of five-
724	membered heterocyclic aldehydic compounds, J Med Chem 47(19) (2004) 4665-76.
725	[8] M.H. Steinberg, Sickle cell anemia, the first molecular disease: overview of molecular etiology,
726	pathophysiology, and therapeutic approaches, Scientific World Journal 8 (2008) 1295-324.
727	[9] J.F. Berties, R. Rabinowitz, J. Dobler, Hemoglobin Interaction: modification of solid phase
728	composition in the sickling phenomenon, Science 169(3943) (1970) 375-7.
729	[10] S. Ballas, Sickle cell pain: Second edition, 2015. [11] S.K. Ballas, D.S. Darbari, Boview/eventiow of pain in sickle cell disease. Complement Ther Med 40
73U 721	[11] S.K. Ballas, D.S. Darban, Review/overview of pain in sickle cell disease, complement mer vieu 49
/31 722	(2020) 102527. [12] A Sanyaoly E Agiri C Portram I Procket I Choudhury D Datt A Ibrahim A Macioiko A
732 722	[12] A. Sanyaolu, E. Agin, C. Bertram, E. Brookes, J. Choudhury, D. Datt, A. Ibrahim, A. Matejko, A. Mansfield J. Nikrumah, M. Williams, Current modalities of sickle cell disease management. Plead Sci
735 731	2(A) (2020) 100-116
734	[13] P. Sundd, M.T. Gladwin, F.M. Novelli, Pathonhysiology of Sickle Cell Disease, Annu Rev Pathol 14
736	(2019) 263-292
737	[14] B.P. Yawn, G.R. Buchanan, A.N. Afenvi-Annan, S.K. Ballas, K.L. Hassell, A.H. James, L. Jordan, S.M.
738	Lanzkron, R. Lottenberg, W.I. Savage, P.J. Tanabe, R.F. Ware, M.H. Murad, J.C. Goldsmith, F. Ortiz, R.
739	Fulwood, A. Horton, J. John-Sowah, Management of sickle cell disease: summary of the 2014 evidence-
740	based report by expert panel members. JAMA 312(10) (2014) 1033-48.
741	[15] H. Tran, M. Gupta, K. Gupta, Targeting novel mechanisms of pain in sickle cell disease, Blood
742	130(22) (2017) 2377-2385.
743	[16] D. Lanznaster, D.R. de Assis, P. Corcia, P.F. Pradat, H. Blasco, Metabolomics Biomarkers: A Strategy
744	Toward Therapeutics Improvement in ALS, Front Neurol 9 (2018) 1126.
745	[17] X. Hu, M.G. Adebiyi, J. Luo, K. Sun, T.T. Le, Y. Zhang, H. Wu, S. Zhao, H. Karmouty-Quintana, H. Liu,
746	A. Huang, Y.E. Wen, O.L. Zaika, M. Mamenko, O.M. Pochynyuk, R.E. Kellems, H.K. Eltzschig, M.R.
747	Blackburn, E.T. Walters, D. Huang, H. Hu, Y. Xia, Sustained Elevated Adenosine via ADORA2B Promotes
748	Chronic Pain through Neuro-immune Interaction, Cell Rep 16(1) (2016) 106-119.
749	[18] Y. Zhang, V. Berka, A. Song, K. Sun, W. Wang, W. Zhang, C. Ning, C. Li, Q. Zhang, M. Bogdanov,
750	D.C. Alexander, M.V. Milburn, M.H. Ahmed, H. Lin, M. Idowu, J. Zhang, G.J. Kato, O.Y. Abdulmalik, W.
751	Zhang, W. Dowhan, R.E. Kellems, P. Zhang, J. Jin, M. Safo, A.L. Tsai, H.S. Juneja, Y. Xia, Elevated
752	sphingosine-1-phosphate promotes sickling and sickle cell disease progression, J Clin Invest 124(6)
753	(2014) 2750-61.
754	[19] A. Kihara, Y. Igarashi, Production and release of sphingosine 1-phosphate and the phosphorylated
755	form of the immunomodulator FTY720, Biochim Biophys Acta 1781(9) (2008) 496-502.
756	[20] K. Sun, Y. Zhang, A. D'Alessandro, T. Nemkov, A. Song, H. Wu, H. Liu, M. Adebiyi, A. Huang, Y.E.
757	Wen, M.V. Bogdanov, A. Vila, J. O'Brien, R.E. Kellems, W. Dowhan, A.W. Subudhi, S. Jameson-Van
758	Houten, C.G. Julian, A.T. Lovering, M. Safo, K.C. Hansen, R.C. Roach, Y. Xia, Sphingosine-1-phosphate
759	promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia, Nat
760	Commun 7 (2016) 12086.

- 761 [21] K. Sun, A. D'Alessandro, M.H. Ahmed, Y. Zhang, A. Song, T.P. Ko, T. Nemkov, J.A. Reisz, H. Wu, M.
- Adebiyi, Z. Peng, J. Gong, H. Liu, A. Huang, Y.E. Wen, A.Q. Wen, V. Berka, M.V. Bogdanov, O. Abdulmalik, L. Han, A.L. Tsai, M. Idowu, H.S. Juneja, R.E. Kellems, W. Dowhan, K.C. Hansen, M.K. Safo,
- Yi Abdullialik, L. Hall, A.L. Tsal, M. Idowu, H.S. Julieja, K.E. Kellenis, W. Downall, K.C. Hallsen, M.K. Salo,
 Y. Xia, Structural and Functional Insight of Sphingosine 1-Phosphate-Mediated Pathogenic Metabolic
- 765 Reprogramming in Sickle Cell Disease, Sci Rep 7(1) (2017) 15281.
- [22] Y. Xiong, P. Yang, R.L. Proia, T. Hla, Erythrocyte-derived sphingosine 1-phosphate is essential for
 vascular development, J Clin Invest 124(11) (2014) 4823-8.
- 768 [23] H. Wu, M. Bogdanov, Y. Zhang, K. Sun, S. Zhao, A. Song, R. Luo, N.F. Parchim, H. Liu, A. Huang,
- M.G. Adebiyi, J. Jin, D.C. Alexander, M.V. Milburn, M. Idowu, H.S. Juneja, R.E. Kellems, W. Dowhan, Y.
 Xia, Hypoxia-mediated impaired erythrocyte Lands' Cycle is pathogenic for sickle cell disease, Sci Rep
- 770 Xia, hypoxia-mediated impaired erythrocyte Lands Cycle is pathogenic for sickle cell disease, sci kep
 771 6 (2016) 29637.
- [24] S.P. Welch, L.J. Sim-Selley, D.E. Selley, Sphingosine-1-phosphate receptors as emerging targets for
 treatment of pain, Biochem Pharmacol 84(12) (2012) 1551-62.
- [25] H. Liu, M. Adebiyi, R.R. Liu, A. Song, J. Manalo, Y.E. Wen, A.Q. Wen, T. Weng, J. Ko, M. Idowu, R.E.
- Kellems, H.K. Eltzschig, M.R. Blackburn, H.S. Juneja, Y. Xia, Elevated ecto-5'-nucleotidase: a missing
 pathogenic factor and new therapeutic target for sickle cell disease, Blood Adv 2(15) (2018) 19571968.
- [26] K. Sun, Y. Zhang, M.V. Bogdanov, H. Wu, A. Song, J. Li, W. Dowhan, M. Idowu, H.S. Juneja, J.G.
 Molina, M.R. Blackburn, R.E. Kellems, Y. Xia, Elevated adenosine signaling via adenosine A2B receptor
 induces normal and sickle erythrocyte sphingosine kinase 1 activity, Blood 125(10) (2015) 1643-52.
- 781 [27] Y. Zhang, Y. Dai, J. Wen, W. Zhang, A. Grenz, H. Sun, L. Tao, G. Lu, D.C. Alexander, M.V. Milburn,
- L. Carter-Dawson, D.E. Lewis, W. Zhang, H.K. Eltzschig, R.E. Kellems, M.R. Blackburn, H.S. Juneja, Y. Xia,
 Detrimental effects of adenosine signaling in sickle cell disease, Nat Med 17(1) (2011) 79-86.
- [28] D. Darghouth, B. Koehl, G. Madalinski, J.F. Heilier, P. Bovee, Y. Xu, M.F. Olivier, P. Bartolucci, M.
 Benkerrou, S. Pissard, Y. Colin, F. Galacteros, G. Bosman, C. Junot, P.H. Romeo, Pathophysiology of
 sickle cell disease is mirrored by the red blood cell metabolome, Blood 117(6) (2011) e57-66.
- [29] K.C. Dembele, T. Mintz, C. Veyrat-Durebex, F. Chabrun, S. Chupin, L. Tessier, G. Simard, D. Henrion,
 D. Mirebeau-Prunier, J.M. Chao de la Barca, P.L. Tharaux, P. Reynier, Metabolomic Profiling of Plasma
 and Erythrocytes in Sickle Mice Points to Altered Nociceptive Pathways, Cells 9(6) (2020).
- [30] K.C. Dembele, C. Veyrat-Durebex, G. Aldiouma, S. Chupin, L. Tessier, Y. Goita, M.A. Baraika, M.
- 791 Diallo, B.A. Toure, C. Homedan, D. Mirebeau-Prunier, G. Simard, D. Diallo, B.M. Cisse, P. Reynier, J.M.
- Chao de la Barca, Sickle Cell Disease: Metabolomic Profiles of Vaso-Occlusive Crisis in Plasma and
 Erythrocytes, J Clin Med 9(4) (2020).
- [31] I. Subramanian, S. Verma, S. Kumar, A. Jere, K. Anamika, Multi-omics Data Integration,
 Interpretation, and Its Application, Bioinform Biol Insights 14 (2020) 1177932219899051.
- [32] M.H. Antonelou, A.G. Kriebardis, I.S. Papassideri, Aging and death signalling in mature red cells:
 from basic science to transfusion practice, Blood Transfus 8 Suppl 3 (Suppl 3) (2010) s39-47.
- [33] A. Bogdanova, A. Makhro, J. Wang, P. Lipp, L. Kaestner, Calcium in red blood cells-a perilous
 balance, Int J Mol Sci 14(5) (2013) 9848-72.
- [34] R. Hasanato, Alterations in serum levels of copper, zinc, and selenium among children with sickle
 cell anemia, Turk J Med Sci 49(5) (2019) 1287-1291.
- 802 [35] M. Khurana, E.B. Fung, E.P. Vichinsky, E.C. Theil, Dietary nonheme iron is equally bioavailable from
- 803 ferritin or ferrous sulfate in thalassemia intermedia, Pediatr Hematol Oncol 34(8) (2017) 455-467.
- 804 [36] N.A. Sopko, H. Matsui, J.L. Hannan, D. Berkowitz, H.C. Champion, L.L. Hsu, B. Musicki, A.L. Burnett,
- T.J. Bivalacqua, Subacute Hemolysis in Sickle Cell Mice Causes Priapism Secondary to NO Imbalance
 and PDE5 Dysregulation, J Sex Med 12(9) (2015) 1878-85.
- 807 [37] S.C. Wilschefski, M.R. Baxter, Inductively Coupled Plasma Mass Spectrometry: Introduction to 808 Analytical Aspects, Clin Biochem Rev 40(3) (2019) 115-133.
- 809 [38] R. Culp-Hill, A.J. Srinivasan, S. Gehrke, R. Kamyszek, A. Ansari, N. Shah, I. Welsby, A. D'Alessandro,
- 810 Effects of red blood cell (RBC) transfusion on sickle cell disease recipient plasma and RBC metabolism,
- 811 Transfusion 58(12) (2018) 2797-2806.

- 812 [39] A. D'Alessandro, S.M. Nouraie, Y. Zhang, F. Cendali, F. Gamboni, J.A. Reisz, X. Zhang, K.W. Bartsch,
- 813 M.D. Galbraith, V.R. Gordeuk, M.T. Gladwin, In vivo evaluation of the effect of sickle cell hemoglobin
- 814 S, C and therapeutic transfusion on erythrocyte metabolism and cardiorenal dysfunction, Am J 815 Hematol (2023).
- [40] S.R. Goodman, B.S. Pace, K.C. Hansen, A. D'Alessandro, Y. Xia, O. Daescu, S.J. Glatt, Minireview:
 Multiomic candidate biomarkers for clinical manifestations of sickle cell severity: Early steps to
 precision medicine, Exp Biol Med (Maywood) 241(7) (2016) 772-81.
- 819 [41] A.L. Okwi, M. Ocaido, W. Byarugaba, C.M. Ndugwa, A. Parkes, Sickling and solubility tests and the
- peripheral blood film method for screening for sickle cell disease. [corrected], S Afr Med J 99(12)(2009) 887-91.
- 822 [42] T. Sana, S. Fischer, S.J.A.T. Clara, Maximizing metabolite extraction for comprehensive 823 metabolomics studies of erythrocytes, (2007) 5989-7407EN.
- [43] Z. Pang, G. Zhou, J. Ewald, L. Chang, O. Hacariz, N. Basu, J. Xia, Using MetaboAnalyst 5.0 for LCHRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics
 data, Nat Protoc 17(8) (2022) 1735-1761.
- 827 [44] M.A. Rizvi, Z. Hussain, F. Ali, A. Amin, S.H. Mir, G. Rydzek, R.M. Jagtap, S.K. Pardeshi, R.A. Qadri,
- K. Ariga, Bioactive supra decorated thiazolidine-4-carboxylic acid derivatives attenuate cellular
 oxidative stress by enhancing catalase activity, Phys Chem Chem Phys 22(15) (2020) 7942-7951.
- [45] G. Bosman, Disturbed Red Blood Cell Structure and Function: An Exploration of the Role of Red
 Blood Cells in Neurodegeneration, Front Med (Lausanne) 5 (2018) 198.
- [46] E. Szczesny-Malysiak, J. Dybas, A. Blat, K. Bulat, K. Kus, M. Kaczmarska, A. Wajda, K. Malek, S.
 Chlopicki, K.M. Marzec, Irreversible alterations in the hemoglobin structure affect oxygen binding in
- human packed red blood cells, Biochim Biophys Acta Mol Cell Res 1867(11) (2020) 118803.
- 835 [47] G. Tomaiuolo, Biomechanical properties of red blood cells in health and disease towards 836 microfluidics, Biomicrofluidics 8(5) (2014) 051501.
- [48] N. Cilek, E. Ugurel, E. Goksel, O. Yalcin, Signaling mechanisms in red blood cells: A view through
 the protein phosphorylation and deformability, J Cell Physiol (2023).
- [49] H. Li, G. Lykotrafitis, Erythrocyte membrane model with explicit description of the lipid bilayerand the spectrin network, Biophys J 107(3) (2014) 642-653.
- [50] V. Pretini, M.H. Koenen, L. Kaestner, M. Fens, R.M. Schiffelers, M. Bartels, R. Van Wijk, Red Blood
 Cells: Chasing Interactions, Front Physiol 10 (2019) 945.
- [51] S.L. Spitalnik, D.V. Devine, Translating red cell "omics" into new perspectives in transfusion
 medicine: mining the gems in the data mountains, Transfusion 59(1) (2019) 2-5.
- [52] C. Tang, Q. Meng, K. Zhang, T. Zhan, Q. Zhao, S. Zhang, J. Zhang, Multi-omics analyses of red blood
 cell reveal antioxidation mechanisms associated with hemolytic toxicity of gossypol, Oncotarget 8(61)
 (2017) 103693-103709.
- 848 [53] A. Iolascon, I. Andolfo, R. Russo, Advances in understanding the pathogenesis of red cell 849 membrane disorders, Br J Haematol 187(1) (2019) 13-24.
- 850 [54] M. Cascella, S. Vaqar, Hypermagnesemia, StatPearls, Treasure Island (FL), 2023.
- [55] A.O. Olukoga, H.O. Adewoye, R.T. Erasmus, M.A. Adedoyin, Erythrocyte and plasma magnesium
 in sickle-cell anaemia, East Afr Med J 67(5) (1990) 348-54.
- [56] A.O. Olukoga, R.T. Erasmus, H.O. Adewoye, Erythrocyte and plasma magnesium status in
 Nigerians with diabetes mellitus, Ann Clin Biochem 26 (Pt 1) (1989) 74-7.
- [57] C. Antwi-Boasiako, Y.A. Kusi-Mensah, C. Hayfron-Benjamin, R. Aryee, G.B. Dankwah, L.A.
 Kwawukume, E.O. Darkwa, Total Serum Magnesium Levels and Calcium-To-Magnesium Ratio in Sickle
- 857 Cell Disease, Medicina (Kaunas) 55(9) (2019).
- 858 [58] O.O. Yousif, M.K. Hassan, L.M. Al-Naama, Red Blood Cell and Serum Magnesium Levels Among
- Children and Adolescents With Sickle Cell Anemia, Biol Trace Elem Res 186(2) (2018) 295-304.
- 860 [59] B.F. Cameron, P. Smariga, Calcium exchange and calcium-related effects in normal and sickle cell
- anemia erythrocytes, Prog Clin Biol Res 20 (1978) 105-22.

- [60] V. Malinovska, P. Matonoha, V. D'Andrea, L. Malinovsky, A. Zechmeister, The role of calcium in
 the effect of stress hormones, Cas Lek Cesk 130(22-23) (1991) 631-4.
- 864 [61] E. Nur, B.J. Biemond, H.M. Otten, D.P. Brandjes, J.J. Schnog, C.S. Group, Oxidative stress in sickle
- cell disease; pathophysiology and potential implications for disease management, Am J Hematol 86(6)(2011) 484-9.
- 867 [62] L. Hertz, R. Huisjes, E. Llaudet-Planas, P. Petkova-Kirova, A. Makhro, J.G. Danielczok, S. Egee, M.
- 868 Del Mar Manu-Pereira, R. van Wijk, J.L. Vives Corrons, A. Bogdanova, L. Kaestner, Is Increased
- 869 Intracellular Calcium in Red Blood Cells a Common Component in the Molecular Mechanism Causing
 870 Anemia?, Front Physiol 8 (2017) 673.
- [63] C. Brugnara, L. de Franceschi, S.L. Alper, Inhibition of Ca(2+)-dependent K+ transport and cell
 dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives, J Clin Invest 92(1)
 (1993) 520-6.
- [64] C. Brugnara, D.C. Tosteson, Inhibition of K transport by divalent cations in sickle erythrocytes,
 Blood 70(6) (1987) 1810-5.
- [65] E. Nader, M. Romana, P. Connes, The Red Blood Cell-Inflammation Vicious Circle in Sickle Cell
 Disease, Front Immunol 11 (2020) 454.
- 878 [66] V. Barodka, J.G. Mohanty, A.K. Mustafa, L. Santhanam, A. Nyhan, A.K. Bhunia, G. Sikka, D. Nyhan,
- D.E. Berkowitz, J.M. Rifkind, Nitroprusside inhibits calcium-induced impairment of red blood cell
 deformability, Transfusion 54(2) (2014) 434-44.
- [67] C. Antwi-Boasiako, Y.A. Kusi-Mensah, C. Hayfron-Benjamin, R. Aryee, G.B. Dankwah, K.L. Abla, E.
- 882 Owusu Darkwa, F.A. Botchway, E. Sampene-Donkor, Serum Potassium, Sodium, and Chloride Levels in
- Sickle Cell Disease Patients and Healthy Controls: A Case-Control Study at Korle-Bu Teaching Hospital,
 Accra, Biomark Insights 14 (2019) 1177271919873889.
- [68] S. Pandey, A. Sharma, S. Dahia, V. Shah, V. Sharma, R.M. Mishra, S. Pandey, R. Saxena, Biochemical
 indicator of sickle cell disease: preliminary report from India, Indian J Clin Biochem 27(2) (2012) 1915.
- [69] C.T. Noguchi, A.N. Schechter, G.P. Rodgers, Sickle cell disease pathophysiology, Baillieres Clin
 Haematol 6(1) (1993) 57-91.
- [70] D. Manwani, P.S. Frenette, Vaso-occlusion in sickle cell disease: pathophysiology and novel
 targeted therapies, Blood 122(24) (2013) 3892-8.
- [71] J.R. Aluoch, Renal and electrolyte profile in steady state sickle cell disease: observations in
 patients with sickle cell disease in The Netherlands, Trop Geogr Med 41(2) (1989) 128-32.
- [72] J.R. Asirvatham, V. Moses, L. Bjornson, Errors in potassium measurement: a laboratory
 perspective for the clinician, N Am J Med Sci 5(4) (2013) 255-9.
- [73] S. Tomlinson, P.D. Mathialagan, S.K. Maloney, Special K: testing the potassium link between
 radioactive rubidium (86Rb) turnover and metabolic rate, J Exp Biol 217(Pt 7) (2014) 1040-5.
- [74] H.L. Meltzer, R.M. Taylor, S.R. Platmann, R.R. Fieve, Rubidium: a potential modifier of affect and
 behaviour, Nature 223(5203) (1969) 321-2.
- 900 [75] N. Rahimi, M. Hassanipour, F. Yarmohammadi, H. Faghir-Ghanesefat, N. Pourshadi, E.
 901 Bahramnejad, A.R. Dehpour, Nitric oxide and glutamate are contributors of anti-seizure activity of
 902 rubidium chloride: A comparison with lithium, Neurosci Lett 708 (2019) 134349.
- 903 [76] L. Xiao, G. Zan, J. Qin, X. Wei, G. Lu, X. Li, H. Zhang, Y. Zou, L. Yang, M. He, Z. Zhang, X. Yang,
- Combined exposure to multiple metals and cognitive function in older adults, Ecotoxicol Environ Saf 222 (2021) 112465.
- 906 [77] N. Kordjazy, A. Haj-Mirzaian, S. Amiri, S. Ostadhadi, M. Kordjazy, M. Sharifzadeh, A.R. Dehpour,
- 907 Elevated level of nitric oxide mediates the anti-depressant effect of rubidium chloride in mice, Eur J
 908 Pharmacol 762 (2015) 411-8.
- 909 [78] S. Martin, M.C. Roderick, C. Abel, P. Wolters, M.A. Toledo-Tamula, C. Fitzhugh, M. Hsieh, J. Tisdale,
- 910 Neurocognitive functioning in symptomatic adults with sickle cell disease: A description and
- 911 comparison with unaffected siblings, Neuropsychol Rehabil 30(9) (2020) 1666-1681.

- 912 [79] C.T. Hijmans, K. Fijnvandraat, M.A. Grootenhuis, N. van Geloven, H. Heijboer, M. Peters, J.
- 913 Oosterlaan, Neurocognitive deficits in children with sickle cell disease: a comprehensive profile, 914 Pediatr Blood Cancer 56(5) (2011) 783-8.
- [80] S.K. Ballas, Neurocognitive complications of sickle cell anemia in adults, JAMA 303(18) (2010)1862-3.
- 917 [81] L.O. Matondo, E. Kija, K.P. Manji, Neurocognitive Functioning among Children with Sickle Cell 918 Anemia Attending SCA Clinic at MNH, Dar es Salaam, Tanzania, Neurol Res Int 2020 (2020) 3636547.
- 919 [82] N.S. Green, D. Munube, P. Bangirana, L.R. Buluma, B. Kebirungi, R. Opoka, E. Mupere, P. Kasirye,
- 920 S. Kiguli, A. Birabwa, M.S. Kawooya, S.K. Lubowa, R. Sekibira, E. Kayongo, H. Hume, M. Elkind, W. Peng,
- 921 G. Li, C. Rosano, P. LaRussa, F.J. Minja, A. Boehme, R. Idro, Burden of neurological and neurocognitive
- 922 impairment in pediatric sickle cell anemia in Uganda (BRAIN SAFE): a cross-sectional study, BMC
 923 Pediatr 19(1) (2019) 381.
- [83] A.A. Hegazy, M.M. Zaher, M.A. Abd El-Hafez, A.A. Morsy, R.A. Saleh, Relation between anemia
 and blood levels of lead, copper, zinc and iron among children, BMC Res Notes 3 (2010) 133.
- 926 [84] M.M. Lubran, Lead toxicity and heme biosynthesis, Ann Clin Lab Sci 10(5) (1980) 402-13.
- 927 [85] J. Schwartz, P.J. Landrigan, E.L. Baker, Jr., W.A. Orenstein, I.H. von Lindern, Lead-induced anemia:
- dose-response relationships and evidence for a threshold, Am J Public Health 80(2) (1990) 165-8.
- 929 [86] C.G. Drossos, K.T. Mavroidis, Z. Papadopoulou-Daifotis, D.N. Michalodimitrakis, L.X. Salamalikis,
- A.K. Gounaris, D.D. Varonos, Environmental lead pollution in Greece, Am Ind Hyg Assoc J 43(10) (1982)
 796-8.
- 932 [87] I.H. Elkhidir, S.S. Ali, W.K. Ali, H.R. Madani, R.A. Basheir, R.M. Altayeb, R.H.S. Shazali, S.
- Fadlelmoula, W.M. Eltayeb, Z.I. Omar, M. Elnil, S.O.O. Mohamed, Zinc, Magnesium, and Copper Levels
 in Patients with Sickle Cell Disease: A Systematic Review and Meta-analysis, Avicenna J Med 12(2)
 (2022) 45-53.
- [88] A. Ece, B.S. Uyanik, A. Iscan, P. Ertan, M.R. Yigitoglu, Increased serum copper and decreased serum
 zinc levels in children with iron deficiency anemia, Biol Trace Elem Res 59(1-3) (1997) 31-9.
- [89] S. Turgut, A. Polat, M. Inan, G. Turgut, G. Emmungil, M. Bican, T.Y. Karakus, O. Genc, Interaction
 between anemia and blood levels of iron, zinc, copper, cadmium and lead in children, Indian J Pediatr
 74(9) (2007) 827-30.
- [90] I.J. Newhouse, D.B. Clement, C. Lai, Effects of iron supplementation and discontinuation on serum
 copper, zinc, calcium, and magnesium levels in women, Med Sci Sports Exerc 25(5) (1993) 562-71.
- 943 [91] H.C. Kim, N.P. Dugan, J.H. Silber, M.B. Martin, E. Schwartz, K. Ohene-Frempong, A.R. Cohen,
 944 Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell
 945 disease, Blood 83(4) (1994) 1136-42.
- [92] K.R. Rao, A.R. Patel, P. McGinnis, M.K. Patel, Iron stores in adults with sickle cell anemia, J Lab Clin
 Med 103(5) (1984) 792-7.
- 948 [93] L. Flohe, W.A. Gunzler, H.H. Schock, Glutathione peroxidase: a selenoenzyme, FEBS Lett 32(1) 949 (1973) 132-4.
- [94] J.T. Rotruck, A.L. Pope, H.E. Ganther, A.B. Swanson, D.G. Hafeman, W.G. Hoekstra, Selenium:
 biochemical role as a component of glutathione peroxidase, Science 179(4073) (1973) 588-90.
- [95] S. Li, W. Sun, K. Zhang, J. Zhu, X. Jia, X. Guo, Q. Zhao, C. Tang, J. Yin, J. Zhang, Selenium deficiency
 induces spleen pathological changes in pigs by decreasing selenoprotein expression, evoking oxidative
 stress, and activating inflammation and apoptosis, J Anim Sci Biotechnol 12(1) (2021) 65.
- 955 [96] G.F. Combs, Jr., W.P. Gray, Chemopreventive agents: selenium, Pharmacol Ther 79(3) (1998) 179-956 92.
- 957 [97] R. Irons, B.A. Carlson, D.L. Hatfield, C.D. Davis, Both selenoproteins and low molecular weight
- 958 selenocompounds reduce colon cancer risk in mice with genetically impaired selenoprotein 959 expression, J Nutr 136(5) (2006) 1311-7.
- 960 [98] R. Scott, A. MacPherson, R.W. Yates, B. Hussain, J. Dixon, The effect of oral selenium 961 supplementation on human sperm motility, Br J Urol 82(1) (1998) 76-80.

- [99] M.P. Look, J.K. Rockstroh, G.S. Rao, K.A. Kreuzer, S. Barton, H. Lemoch, T. Sudhop, J. Hoch, K.
 Stockinger, U. Spengler, T. Sauerbruch, Serum selenium, plasma glutathione (GSH) and erythrocyte
 glutathione peroxidase (GSH-Px)-levels in asymptomatic versus symptomatic human
 immunodeficiency virus-1 (HIV-1)-infection, Eur J Clin Nutr 51(4) (1997) 266-72.
- 966 [100] L. Kiremidjian-Schumacher, M. Roy, Effect of selenium on the immunocompetence of patients
 967 with head and neck cancer and on adoptive immunotherapy of early and established lesions,
 968 Biofactors 14(1-4) (2001) 161-8.
- 969 [101] C.R. Morris, J.H. Suh, W. Hagar, S. Larkin, D.A. Bland, M.H. Steinberg, E.P. Vichinsky, M.
 970 Shigenaga, B. Ames, F.A. Kuypers, E.S. Klings, Erythrocyte glutamine depletion, altered redox
 971 environment, and pulmonary hypertension in sickle cell disease, Blood 111(1) (2008) 402-10.
- 972 [102] S.R. Goodman, The irreversibly sickled cell: a perspective, Cell Mol Biol (Noisy-le-grand) 50(1) 973 (2004) 53-8.
- 974 [103] M. Aslan, D. Thornley-Brown, B.A. Freeman, Reactive species in sickle cell disease, Ann N Y Acad
 975 Sci 899 (2000) 375-91.
- 976 [104] F.Q. Schafer, G.R. Buettner, Redox environment of the cell as viewed through the redox state of 977 the glutathione disulfide/glutathione couple, Free Radic Biol Med 30(11) (2001) 1191-212.
- 978 [105] M.C. Garel, C. Domenget, J. Caburi-Martin, C. Prehu, F. Galacteros, Y. Beuzard, Covalent binding
- 979 of glutathione to hemoglobin. I. Inhibition of hemoglobin S polymerization, J Biol Chem 261(31) (1986)
- 980 14704-9.
- [106] M. Reid, A. Badaloo, T. Forrester, F. Jahoor, In vivo rates of erythrocyte glutathione synthesis in
 adults with sickle cell disease, Am J Physiol Endocrinol Metab 291(1) (2006) E73-9.
- [107] R. Franco, O.J. Schoneveld, A. Pappa, M.I. Panayiotidis, The central role of glutathione in the
 pathophysiology of human diseases, Arch Physiol Biochem 113(4-5) (2007) 234-58.
- [108] J.E. Snoke, K. Bloch, Studies on the mechanism of action of glutathione synthetase, J Biol Chem
 213(2) (1955) 825-35.
- 987 [109] S.C. Rogers, A. Said, D. Corcuera, D. McLaughlin, P. Kell, A. Doctor, Hypoxia limits antioxidant 988 capacity in red blood cells by altering glycolytic pathway dominance, FASEB J 23(9) (2009) 3159-70.
- 989 [110] W.G. Siems, O. Sommerburg, T. Grune, Erythrocyte free radical and energy metabolism, Clin 990 Nephrol 53(1 Suppl) (2000) S9-17.
- [111] P.S. Low, P. Rathinavelu, M.L. Harrison, Regulation of glycolysis via reversible enzyme binding to
 the membrane protein, band 3, J Biol Chem 268(20) (1993) 14627-31.
- 993 [112] I. Messana, M. Orlando, L. Cassiano, L. Pennacchietti, C. Zuppi, M. Castagnola, B. Giardina,
 994 Human erythrocyte metabolism is modulated by the O2-linked transition of hemoglobin, FEBS Lett
 995 390(1) (1996) 25-8.
- [113] D. Sterling, R.A. Reithmeier, J.R. Casey, A transport metabolon. Functional interaction of carbonic
 anhydrase II and chloride/bicarbonate exchangers, J Biol Chem 276(51) (2001) 47886-94.
- 998 [114] L.J. Bruce, R. Beckmann, M.L. Ribeiro, L.L. Peters, J.A. Chasis, J. Delaunay, N. Mohandas, D.J.
- Anstee, M.J. Tanner, A band 3-based macrocomplex of integral and peripheral proteins in the RBCmembrane, Blood 101(10) (2003) 4180-8.
- 1001 [115] N.N. Barvitenko, N.C. Adragna, R.E. Weber, Erythrocyte signal transduction pathways, their 1002 oxygenation dependence and functional significance, Cell Physiol Biochem 15(1-4) (2005) 1-18.
- 1003 [116] M.E. Campanella, H. Chu, P.S. Low, Assembly and regulation of a glycolytic enzyme complex on 1004 the human erythrocyte membrane, Proc Natl Acad Sci U S A 102(7) (2005) 2402-7.
- 1005 [117] H. Chu, P.S. Low, Mapping of glycolytic enzyme-binding sites on human erythrocyte band 3,1006 Biochem J 400(1) (2006) 143-51.
- 1007 [118] H. Chu, A. Breite, P. Ciraolo, R.S. Franco, P.S. Low, Characterization of the deoxyhemoglobin
- binding site on human erythrocyte band 3: implications for O2 regulation of erythrocyte properties,Blood 111(2) (2008) 932-8.
- 1010 [119] B.S. Kirby, G. Hanna, H.C. Hendargo, T.J. McMahon, Restoration of intracellular ATP production
- 1011 in banked red blood cells improves inducible ATP export and suppresses RBC-endothelial adhesion,
- 1012 Am J Physiol Heart Circ Physiol 307(12) (2014) H1737-44.

- [120] S.C. Rogers, J.G. Ross, A. d'Avignon, L.B. Gibbons, V. Gazit, M.N. Hassan, D. McLaughlin, S. Griffin,
 T. Neumayr, M. Debaun, M.R. DeBaun, A. Doctor, Sickle hemoglobin disturbs normal coupling among
- 1015 erythrocyte O2 content, glycolysis, and antioxidant capacity, Blood 121(9) (2013) 1651-62.
- [121] E. Ferru, K. Giger, A. Pantaleo, E. Campanella, J. Grey, K. Ritchie, R. Vono, F. Turrini, P.S. Low,
 Regulation of membrane-cytoskeletal interactions by tyrosine phosphorylation of erythrocyte band 3,
- 1018 Blood 117(22) (2011) 5998-6006.
- [122] R.L. Sabina, N.J. Wandersee, C.A. Hillery, Ca2+-CaM activation of AMP deaminase contributes to
 adenine nucleotide dysregulation and phosphatidylserine externalization in human sickle
 erythrocytes, Br J Haematol 144(3) (2009) 434-45.
- 1022 [123] M.F. Leal Denis, J.J. Incicco, M.V. Espelt, S.V. Verstraeten, O.P. Pignataro, E.R. Lazarowski, P.J.
 1023 Schwarzbaum, Kinetics of extracellular ATP in mastoparan 7-activated human erythrocytes, Biochim
 1024 Biophys Acta 1830(10) (2013) 4692-707.
- 1025 [124] B.S. Kirby, M.A. Sparks, E.R. Lazarowski, D.A. Lopez Domowicz, H. Zhu, T.J. McMahon, Pannexin
 1026 1 channels control the hemodynamic response to hypoxia by regulating O(2)-sensitive extracellular
 1027 ATP in blood, Am J Physiol Heart Circ Physiol 320(3) (2021) H1055-H1065.
- 1028 [125] H. Zhu, R. Zennadi, B.X. Xu, J.P. Eu, J.A. Torok, M.J. Telen, T.J. McMahon, Impaired adenosine-5'-
- triphosphate release from red blood cells promotes their adhesion to endothelial cells: a mechanism
 of hypoxemia after transfusion, Crit Care Med 39(11) (2011) 2478-86.
- 1031 [126] P. Van der Werf, M. Orlowski, A. Meister, Enzymatic conversion of 5-oxo-L-proline (L-pyrrolidone
 1032 carboxylate) to L-glutamate coupled with cleavage of adenosine triphosphate to adenosine
 1033 diphosphate, a reaction in the -glutamyl cycle, Proc Natl Acad Sci U S A 68(12) (1971) 2982-5.
- 1034 [127] M. Watanabe, M. Kusano, A. Oikawa, A. Fukushima, M. Noji, K. Saito, Physiological roles of the 1035 beta-substituted alanine synthase gene family in Arabidopsis, Plant Physiol 146(1) (2008) 310-20.
- [128] J.J. Abbott, J. Pei, J.L. Ford, Y. Qi, V.N. Grishin, L.A. Pitcher, M.A. Phillips, N.V. Grishin, Structure
 prediction and active site analysis of the metal binding determinants in gamma -glutamylcysteine
 synthetase, J Biol Chem 276(45) (2001) 42099-107.
- 1039 [129] P.G. Richman, A. Meister, Regulation of gamma-glutamyl-cysteine synthetase by nonallosteric 1040 feedback inhibition by glutathione, J Biol Chem 250(4) (1975) 1422-6.
- 1041 [130] A.K. Bachhawat, S. Yadav, The glutathione cycle: Glutathione metabolism beyond the gamma-1042 glutamyl cycle, IUBMB Life 70(7) (2018) 585-592.
- 1043 [131] Z. He, X. Sun, S. Wang, D. Bai, X. Zhao, Y. Han, P. Hao, X.S. Liu, Ggct (gamma-glutamyl 1044 cyclotransferase) plays an important role in erythrocyte antioxidant defense and red blood cell 1045 survival, Br J Haematol 195(2) (2021) 267-275.
- 1046 [132] S. Kageyama, E. Hanada, H. Ii, K. Tomita, T. Yoshiki, A. Kawauchi, Gamma-1047 Glutamylcyclotransferase: A Novel Target Molecule for Cancer Diagnosis and Treatment, Biomed Res 1048 Int 2015 (2015) 345219.
- 1049 1050

1050

1051

1053

1054

1055 1056

1057

1058 1059

1060

1061

1062

1063

1066List of Abbreviation1067

- 1068 SCD, Sickle cell disease
- 1069 ICP-MS, Inductively coupled plasma mass spectrometry
- 1070 LC-MS, Liquid chromatography-mass spectrometry
- 1071 RBC, Red blood cell
- 1072 SS-RBCs, sickle shaped RBCs (SS-RBCs)
- 1073 WHO, World health organisation
- 1074 VOC, Vaso-occlusive crisis
- 1075 Hb, hemoglobin
- 1076 HbA, adult hemoglobin
- 1077 HbS, sickle cell hemoglobin
- 1078 HbF, Fetal hemoglobin
- 1079 VOC, Vaso-Occlusive crisis
- 1080 QoL, quality of life
- 1081 HSCT, hematopoietic stem cell transplantation
- 1082 O₂, Oxygen
- 1083 HbS-O₂, Oxygenated sickle hemoglobin
- 1084 p50, the pressure at which hemoglobin is 50% saturated
- 1085 ROS, reactive oxygen species
- 1086 pO_2 , partial pressure of oxygen
- 1087 Tg, Transgenic
- 1088 ADORA2B, Adenosine A2b Receptor
- 1089 S1P, sphingosine-1-phosphate (S1P)
- 1090 EMP, Embden Meyerhoff pathway
- 1091 HMP, Hexose monophosphate pathway
- 1092 2, 3-DPG, 2,3 Diphosphoglyceric Acid
- 1093 2, 3-BPG, 2, 3 Bisphosphoglyceric acid
- 1094 S1PR1, S1P receptor 1
- 1095 SphK1, Sphingosine Kinase-1
- 1096 ADA, Adenosine deaminase deficiency
- 1097 PEG-ADA, Polyethylene glycol-modified adenosine deaminase
- 1098 CD73, ecto-5'-nucleotidase
- 1099 CAR, Central African Republic (BAN or CAR)
- 1100 CAM, Cameroon
- 1101 BEN, Benin
- 1102 SEN, Senegal
- 1103 ARB/AI, Arab-Indian
- 1104 HbSS, Homozygous sickle cell disease/Sickle cell disease
- 1105 HbAS, Hetrozygous sickle cell trait/ Sickle cell trait
- 1106 HbAA, Homozygous normal/ Healthy control
- 1107 HC, Healthy control
- 1108 CBC, Complete blood count
- 1109 PCR, Polymerase chain reaction
- 1110 HPLC, High performance liquid chromatography
- 1111 HCD, Higher-energy C-trap dissociation
- 1112 OPLS-DA, orthogonal projections to latent structures discriminant analysis
- 1113 FDR, false discovery rate
- 1114 PCA, principal component analysis
- 1115 SVM, Linear support vector machine

- 1116 MCCV, Monte-Carlo cross-validation
- 1117 ROC, receiver operating characteristic
- 1118 AUROC, Area under ROC
- 1119 H_2O_2 , Hydrogen peroxide
- 1120 HNO₃, Nitric acid
- 1121 N₂, Nitrogen
- 1122 ²⁴Mg, Magnesium
- 1123 ⁴⁴Ca, Calcium
- 1124 ⁵⁷Fe, Iron
- 1125 ⁶³Cu, Copper
- 1126 ⁶⁶Zn, Zinc
- 1127 ⁷⁷Se, Selenium
- 1128 ⁸⁵Rb, Rubidium
- 1129 ²⁰⁸Pb, Lead
- 1130 ³⁹K, Potassium
- 1131 Hb-O₂, oxyhemoglobin
- 1132 KCC1/3/4, K-Cl co-transporter
- 1133 IQ, Intelligent quotient,
- 1134 BLL, Blood lead level
- 1135 HCT, Hematocrit
- 1136 HGB, Hemoglobin (g/dl)
- 1137 MCHC, Mean corpuscular hemoglobin concentration
- 1138 NADPH, Nicotinamide adenine dinucleotide phosphate
- 1139 GSH, reduced glutathione
- 1140 GSSG, oxidized (GSSG)
- 1141 G-Hb, glutathiol-hemoglobin
- 1142 DPT, dipeptidases (DPT)
- 1143 GGCS, gamma-glutamylcysteine synthetase (G-GCS)
- 1144 γ -GCT/GGCT, gamma-glutamyl cyclotransferase (G-GCT)
- 1145 OXP, oxoprolinase
- 1146 GGT, gamma-glutamyl transpeptidase
- 1147 ATP, Adenosine triphosphate
- 1148 cdB3, Band 3
- 1149 γ -GCS/GGCS, gamma-glutamylcysteine synthetase
- 1150 GS, GSH sythetase
- 1151

- 1153
- 1154
- 1155
- 1156
- 1157
- 1158 1159
- 1160
- 1161
- 1162
- 1163
- 1164
- 1165